ECP002A (Δ9-THC) in MS patients
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Dronabinol
Cannabinoid CB1 receptor agonist
What it measured
Main measures
The difference in the severity of spasticity: defined by the H-reflex/M-wave amplitude ratio.
Spasticity
Other measures (1)
Dose Finding
Who could take part
MS (type not specified)
Inclusion: 1. Subject is legally competent; Exclusion: 1. Baseline Expanded Disability Status Scale (EDSS) score < 4.5 or > 7.5;
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Evaluation of the efficacy of ECP002A (Δ9-THC) on spasticity in patients with MS
Loading reviews and guidelines…
Related trials
- ICE Trial
Phase 4 · Ongoing (inferred)
Still running
- A Study to Investigate Arbaclofen ER Tablets for the Trea…
Phase 3 · Not yet recruiting
Still running
- Cannabis (THC vs. CBD) in Multiple Sclerosis
Phase 2 · Recruiting
Still running
- ICE
Phase 4 · Recruiting
Still running
- DRI_2020/03
Phase 3 · Not yet recruiting
Still running
- Mechanisms of Cannabidiol in Persons With MS: the Role of…
Phase 2 · Recruiting
Still running
History
Started
Oct 2010
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error